Page 114 - Eceptor News Today

A screening tool developed at the University of Strathclyde, UK, could increase the number of tests on a solid tumor sample by up to 50 times.

Acute kidney injury (AKI) is a condition in which kidneys are unable to filter waste from the blood effectively, leading to various health complications.

In a new study, researchers uncovered the organization of nausea-associated brainstem circuits to show that selectively blocking the excitatory neurons responsive to nausea-promoting growth/differentiation factor 15 suppresses nausea-related behaviors.

Researchers demonstrated that impaired type I interferon immunity is associated with increasing coronavirus disease 2019 severity.

Hypothalamic GABAergic neurons recognize microbial muropeptides through the cytosolic receptor NOD2, which regulates food intake and body temperature.

In a recent study published in the journal Nature Medicine, researchers assessed the coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) against symptomatic infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) and variants of interest (VOIs) by genetic mismatch/distance (GD) analysis.

According to UCLA scientists working with Stanford and University of Pennsylvania experts, a synthetic IL-9 receptor permits cancer-fighting T cells to accomplish their job without the usage of chemo or radiation.

According to the researchers at the University of Pennsylvania, synthetic IL-9 receptor allows cancer-fighting T cells to do their job without the use of chemo or radiation.

In a recent study posted to the bioRxiv* pre-print server, researchers developed a novel Binding Activated Tandem split enzyme (BAT) biosensor for the detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein.

In a recent study posted to the bioRxiv* pre-print server, researchers provide the first preclinical evidence of the usefulness of antagonists of G-protein coupled receptor 183 (GPR183), also known as Epstein-Barr virus-induced gene 2 (EBI2), in reducing coronavirus disease 2019 (COVID-19) severity.